ReviewAnnals of gastroenterological surgery2018
Cancer evolution and heterogeneity.
Review in Annals of gastroenterological surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- The impact of neoadjuvant chemotherapy on immunohistochemistry and molecular subtype in breast cancer: A retrospective analysis from Oman.Qatar medical journal · 2026Article
- ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 Activation.Cancer science · 2026Article
- The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions.Cancer research communications · 2025Article
- Decoding breast cancer heterogeneity: a novel three-gene signature links intratumoral heterogeneity with tumor microenvironment and patient outcomes.Discover oncology · 2025Article
- The heterogeneity in oligoprogression and stereotactic body radiation therapy.Translational cancer research · 2025Article
- Article
- Cancer metabolism challenges genomic instability and clonal evolution as therapeutic targets.Cancer science · 2022Review
- An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.Frontiers in medicine · 2022Article
- DNA Repair-Related Gene Signature in Predicting Prognosis of Colorectal Cancer Patients.Frontiers in genetics · 2022Article
- Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis.Molecular medicine (Cambridge, Mass.) · 2021Article
- Epithelial Cell Transformation and Senescence as Indicators of Genome Aging: Current Advances and Unanswered Questions.International journal of molecular sciences · 2021Review
- Genome-Wide Analysis Reveals Hypoxic Microenvironment Is Associated With Immunosuppression in Poor Survival of Stage II/III Colorectal Cancer Patients.Frontiers in medicine · 2021Article
- Clinical implications of cancer stem cells in digestive cancers: acquisition of stemness and prognostic impact.Surgery today · 2020Review
- PLK2 modulation of enriched TAp73 affects osteogenic differentiation and prognosis in human osteosarcoma.Cancer medicine · 2020Article
- Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity.Frontiers in molecular biosciences · 2020Review
- Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity.PloS one · 2020Article
- Expression profile analysis of two antisense lncRNAs to improve prognosis prediction of colorectal adenocarcinoma.Cancer cell international · 2019Article
- Cancer evolution and heterogeneity.Annals of gastroenterological surgery · 2018Review
- Construction of Radiation Surviving/Resistant Lung Cancer Cell Lines with Equidifferent Gradient Dose Irradiation.Dose-response : a publication of International Hormesis SocietyArticle
- An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Undoubtedly, intratumor heterogeneity (ITH) is one of the causes of the intractability of cancers. Recently, technological innovation in genomics has promoted studies on ITH in solid tumors and on the pattern and level of diversity, which varies among malignancies. We profiled the genome in multiple regions of nine colorectal cancer (CRC) cases. The most impressive finding was that in the late phase, a parental clone branched into numerous subclones. We found that minor mutations were dominant in advanced CRC named neutral evolution; that is, driver gene aberrations were observed with high proportion in the early-acquired phase, but low in the late-acquired phase. Then, we validated that neutral evolution could cause ITH in advanced CRC by super-computational analysis. According to the clinical findings, we explored a branching evolutionary process model in cancer evolution, which assumes that each tumor cell has cellular automaton. According to the model, we verified factors to foster ITH with neutral evolution in advanced CRC. In this review, we introduce recent advances in the field of ITH including the general component of ITH, clonal selective factors that consolidate the evolutionary process, and a representative clinical application of ITH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.